Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas.

0-100 μg/mL Brontictuzumab effectively inhibited the activity of Notch1 signaling pathways, including DLL4 and JAG1/2. In HPB-ALL cell line, treatment with 25 μg/mL Brontictuzumab for 4 days significantly reduced the level of Notch1 intracellular structural domain. [1]
In MCL cells, treatment with 25 μg/mL Brontictuzumab for 48 hours inhibited DLL4-mediated overexpression of cleaved Notch1. In addition, the increased phosphorylation of MEK and ERK in Mino cells caused by DLL4 stimulation was effectively blocked. [2]

In the MCL model, 20 mg/kg Brontictuzumab intraperitoneal injection, administered every 4 days, inhibited DLL4-induced Notch1 activation. [2]
Intraperitoneal injection of 15 mg/kg Brontictuzumab significantly reduced tumor burden in a T-ALL xenograft model. [3]